Healthcare
Personalis, Inc.(PSNL)
Live Price
Offline$10.54
+8.10% today
1Y Change
+57.00%
Window
Jun 23, 2025 β Jun 9, 2026
- Market Cap
- $510.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +33.6%
- Dividend Yield
- 0.0%
Coverage: 242 bars Β· Jun 23, 2025 β Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Personalis, Inc. (PSNL) is a Healthcare stock with a market cap of $510.00M and listed on NASDAQ. The stock last traded around $10.54 and up 57.0% across the available one-year price window (Jun 23, 2025 β Jun 9, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +33.6%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +33.6%, free cash flow -69.9% with operating margin -126.4% and ROIC -29.9%. Valuation sits in the middle of the pack at price/sales 7.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PSNL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
-126.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +33.6%, with operating margin around -126.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | β | +9.2% | +8.6% | +93.9% |
2026 Feb 26, 2026 | +16.1% | +0.3% | -5.2% | -18.9% |
2025 Nov 4, 2025 | +14.3% | -12.3% | -3.3% | +16.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSNL
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
PSNL Max Drawdown
-55.20%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PSNL and SPY.
Company Overview
Personalis, Inc.
NASDAQ Global Market
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
- Leadership
- Christopher Hall
- IPO Date
- Jun 20, 2019
- Employees
- 228
- Street Address
- 1330 OβBrien Drive
- Mailing
- Fremont, CA, 94025
- Region
- Fremont, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 752 1300
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 7.4
- Price/Book
- 2.0
Growth
- Revenue
- -100.0%
- EPS
- +33.6%
- Free Cash Flow
- -69.9%
Profitability
- Gross Margin
- 22.7%
- Operating Margin
- -126.4%
- Net Margin
- -116.7%
- ROE
- -39.1%
- ROIC
- -29.9%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 6.76
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.